ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0090

Lack of Racial and Ethnic Diversity in Clinical Trials of Psoriatic Arthritis

Niti Goel, TrialSpark, Duke University, Durham, NC

Meeting: ACR Convergence 2022

Keywords: clinical trial, Psoriatic arthritis, race/ethnicity

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Healthcare Disparities in Rheumatology Poster

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Participant diversity in clinical trials of therapeutics in rheumatology is important to evaluate to better understand how individuals of different races and ethnicities might respond differently, if at all, to therapeutics. Specifically, for psoriatic arthritis (PsA), although people of color (POC) have lower disease prevalence, it still ranges from 0.04-0.19% in Blacks and 0.09-0.30% in Hispanics versus 0.19-0.34% in Whites in the insured population of the US1. Literature on the diversity of PsA clinical trials and the therapeutic effects on individuals of POC remains limited. This analysis aims to describe the reporting and racial/ethnic distribution of participants in clinical trials of US Food and Drug Administration approved targeted therapies for PsA.

Methods: Targeted therapies approved for use in the treatment of PsA in the US were identified. Package inserts and ClinicalTrials.gov (CT.gov) were used to determine the pivotal double-blind, randomized clinical trials (RCTs) which supported the approval of the therapeutics for PsA in the US, and the articles reporting the primary endpoint data were reviewed. Race and ethnicity data were extracted from the published data. Countries in which the studies were conducted were identified from the publications or CT.gov.

Results: Twenty-nine pivotal RCTs of targeted therapeutics published from 2002 – 2022 were identified; 25 reported race; individuals of non-White race were reported in only 13. In the latter, people of Black race comprised < 1% of the overall population in 12 RCTs and 2.7% in the remaining RCT. People of Asian race comprised < 10% in 11 studies and 11.3% and 19.0% in the remaining 2 studies, though 20 trials occurred in Asia Pacific countries (Figure). Hispanic/Latinx ethnicity was not reported in any study. Later studies (2017-2022) reported non-White race (n=7 of 15 [47%]) no more frequently than studies from 2004-2016 (n=6 of 14 [43%]). Although the 13 RCTs reporting non-White race may not reflect unique individuals, the total number of people studied was 7261, of which 48 (0.7%), 434 (6.0%), and 6598 (90.9%) were Black, Asian, and White, respectively.

Conclusion: These data show continued under-reporting of race and ethnicity in publications of PsA clinical trials. Even when reported, compared to the overall US population of which 72% and 62% were non-Hispanic Whites in 2010 and 2020, respectively, non-Hispanic Whites were over-represented in pivotal trials of PsA. This over-representation is notable when considering the prevalence of PsA by race in the US or that individuals of different races/ethnicity may have been less prevalent in other countries where recruitment occurred. Efforts to increase the reporting of race/ethnicity and ensure adequate representation of racial/ethnic minorities in PsA clinical trials are needed.

References:
1. Ogdie A, et al. Rheumatol Ther. 2021;8(4):1725-39.
2. https://trialfacts.com/diversity-inclusion/ accessed 22 May 2022

Supporting image 1


Disclosures: N. Goel, UCB.

To cite this abstract in AMA style:

Goel N. Lack of Racial and Ethnic Diversity in Clinical Trials of Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/lack-of-racial-and-ethnic-diversity-in-clinical-trials-of-psoriatic-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lack-of-racial-and-ethnic-diversity-in-clinical-trials-of-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology